SAILIFE

Sai Life Science Share Price

 

 

Invest in Sai Life Science with 3.24X leverage

Invest with MTF

Performance

  • Low
  • ₹854
  • High
  • ₹880
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹943
  • Open Price₹880
  • Previous Close₹876
  • Volume246,765

Investment Returns

  • Over 1 Month -1.75%
  • Over 3 Month -0.02%
  • Over 6 Month + 16.67%
  • Over 1 Year + 56.67%

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 63.1
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 18,082
  • P/B Ratio
  • Average True Range
  • 23.53
  • EPS
  • 13.62
  • Dividend Yield
  • 0
  • MACD Signal
  • -3.01
  • RSI
  • 43.01
  • MFI
  • 54.46

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹860.10
-15.8 (-1.8%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹876.45
  • 50 Day
  • ₹875.95
  • 100 Day
  • ₹856.64
  • 200 Day
  • ₹803.67

Resistance and Support

864.68 Pivot Speed
  • R3 901.17
  • R2 890.53
  • R1 875.32
  • S1 849.47
  • S2 838.83
  • S3 823.62

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 2,053.17 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 9% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-07 Quarterly Results
2025-05-13 Audited Results
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

34.93%
26.16%
3.15%
22.49%
0%
7.91%
5.36%

About Sai Life Science

  • NSE Symbol
  • SAILIFE
  • BSE Symbol
  • 544306
  • Managing Director & CEO
  • Mr. Krishnam Raju Kanumuri
  • ISIN
  • INE570L01029

Similar Stocks to Sai Life Science

Sai Life Science FAQs

Sai Life Science share price is ₹860 As on 09 December, 2025 | 04:43

The Market Cap of Sai Life Science is ₹18082.3 Cr As on 09 December, 2025 | 04:43

The P/E ratio of Sai Life Science is 63.1 As on 09 December, 2025 | 04:43

The PB ratio of Sai Life Science is 18.7 As on 09 December, 2025 | 04:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23